Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in
Microsaic Systems (MSYS.L) Trading update for H1 2021
Unaudited revenues up 594% on H1 2020 and 52% on H1 2019, reflecting new business model
Microsaic Systems (MSYS.L) Development of real-time monitoring solution
Microsaic demonstrates real-time monitoring for scaling biotherapeutic production Automated system maintains high quality while allowing rapid scaling to large volumes.
Evgen Pharma PLC (EVG.L) Progress with Glioma/Glioblastoma programme
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma (“GBM”).
Evgen Pharma PLC (EVG.L) SFX-01 to be evaluated in COVID-19 trial
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company, is delighted to announce participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research
Evgen Pharma (EVG.L) Clinical trial that could reduce Covid-19 deaths
The University of Dundee is leading the clinical trial of a new anti-inflammatory drug it is hoped may reduce instances of severe lung damage and death in Covid-19 patients.